Moderna raises 2026 outlook as newer vaccines gain traction

· Health · United States

Moderna raised its 2026 revenue outlook, saying it now expects growth of 15% to 25%, up from previous guidance of up to 10%, as its chief executive said newer vaccines are gaining traction. The improved forecast signals the biotech company is finding new sources of growth beyond its original COVID-19 franchise, which saw demand fall sharply as the pandemic wound down. The guidance update comes as investors scrutinise which vaccine makers can sustain revenue after the pandemic-era surge.

Why it matters：Moderna's outlook is a test of whether pandemic-era vaccine makers can build durable businesses as COVID demand fades.

Key points

  • Moderna now expects 2026 revenue growth of 15% to 25%.
  • Previous guidance was up to 10%.
  • The CEO says newer vaccines are gaining traction.

Sources (original reporting)

More stories from this day